Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (IPHA) news covers the company’s progress as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As a dual-listed issuer on Euronext Paris (IPH) and Nasdaq (IPHA), Innate Pharma regularly publishes regulatory and corporate updates that are relevant to investors following immuno-oncology and antibody-based therapeutics.
News about Innate Pharma frequently highlights developments across its antibody-engineering and ANKET® (Antibody-based NK cell Engager Therapeutics) platform. Company releases describe clinical and regulatory milestones for key assets such as IPH4502, a differentiated Nectin-4 ADC in solid tumors; lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody in cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Investors can expect updates on clinical trial progress, including Phase 1, Phase 2 and Phase 3 studies, regulatory designations for pipeline assets, and collaboration news involving partners such as Sanofi and AstraZeneca. Innate Pharma’s news flow also includes financial communications, such as business updates, financial results, financial calendars, and regulatory disclosures on the number of shares outstanding and voting rights under French market rules.
This news page aggregates these company communications in one place, making it easier to follow Innate Pharma’s clinical pipeline evolution, partnership activities and key corporate events. Readers interested in immuno-oncology, antibody-drug conjugates, NK cell engagers and collaboration-driven biotech models can use this feed to monitor how Innate Pharma reports its progress over time.
Innate Pharma (IPHA) reported progress in its lacutamab TELLOMAK trial, advancing to Stage 2 for KIR3DL2-expressing mycosis fungoides after positive results. The NK cell engager IPH6101 was selected by Sanofi for further development, triggering a €7 million milestone payment. The company reported a cash position of €181.7 million and revenues of €4.5 million for Q1 2021, down from €19.3 million in the same period last year. Innate expects to present additional data from clinical trials later this year.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced a conference call on May 11, 2021, to discuss Q1 2021 business updates. The call will feature CEO Mondher Mahjoubi, CMO Joyson Karakunnel, and CFO Frédéric Lombard. Interested participants can join via webcast or telephone after registering. Innate Pharma focuses on oncology and boasts a diverse pipeline of therapeutic antibodies designed to improve cancer treatment outcomes. Its partnerships with leading biopharmaceutical companies enhance its research capabilities in this sector.
Innate Pharma has filed its 2020 Universal Registration Document with the French AMF and its annual report on Form 20-F with the SEC. Both documents are accessible on the company's website. Innate focuses on oncology with a pipeline of therapeutic antibodies aimed at improving cancer treatments. The company has established significant alliances with major biopharmaceutical firms, enhancing its research capacity. However, the press release warns of risks associated with R&D, clinical trial uncertainties, and potential impacts from COVID-19 on operations.
Innate Pharma SA (Euronext: IPH, Nasdaq: IPHA) announced the filing of its 2020 Universal Registration Document with the French market authority, AMF, and its annual report on Form 20-F with the SEC. Both documents are available on the company’s and the respective authorities' websites. Innate Pharma is a clinical-stage biotech company focused on oncology, with a diverse pipeline of therapeutic antibodies aimed at improving cancer treatment. The company collaborates with major biopharmaceutical firms, enhancing its market position.
Innate Pharma will hold its Annual General Meeting (AGM) on May 28, 2021, at 11:00 a.m. CET. The meeting will be broadcasted live, allowing shareholders to participate via mail or proxy due to health-related restrictions on gatherings.
Shareholders must register their shares two business days before the AGM to vote. Written questions are welcomed until two business days prior, and connection details will be available on the company’s website. For more information, documentation will be accessible through their investor relations email.
Innate Pharma has disclosed its share capital structure as of April 1, 2021. The company has a total of 78,996,240 ordinary shares outstanding, along with 6,806 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 79,799,621, while 79,781,046 are exercisable. This information complies with the French stock market regulations to ensure market transparency.
Innate Pharma focuses on cancer treatment through therapeutic antibodies and partners with major biopharmaceutical firms.
Innate Pharma reported financial results for 2020, revealing a revenue decline of 17.9% to €70.5 million, attributed mainly to a drop in collaboration income from AstraZeneca. The company faced a net loss of €64 million, up from €20.8 million the previous year, partly due to a €43.5 million impairment on Lumoxiti assets after returning commercialization rights to AstraZeneca. Despite challenges, Innate achieved significant milestones, including PRIME designation for lacutamab and a Phase 3 trial startup for monalizumab, contributing to a cash position of €190.6 million by year-end.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) will hold a conference call on March 18, 2021, at 2 p.m. CET / 9 a.m. ET to discuss its financial results for the year ending December 31, 2020. Key executives, including CEO Mondher Mahjoubi and CFO Laure-Hélène Mercier, will provide insights during the call. Participants can join the call via a live webcast or telephone registration, with a replay available for 90 days. Innate Pharma is focused on oncology and has partnerships with major biopharmaceutical firms, emphasizing its commitment to innovative cancer treatments.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced its total number of shares outstanding as of February 1, 2021. The company has 78,989,740 ordinary shares, including 6,856 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights is 79,799,621, while the exercisable voting rights stand at 79,781,046. This disclosure complies with French regulation and emphasizes Innate Pharma's commitment to keeping investors informed regarding shareholding positions and governance.
Innate Pharma SA (Euronext: IPH, Nasdaq: IPHA) announced that its senior management will participate in the 10th Annual SVB Leerink Global Healthcare Conference from February 24-26, 2021. A fireside chat is scheduled on February 24 from 2:00-2:30 p.m. CET / 8:00-8:30 a.m. ET. The event will be available via live webcast on the company's website, with a replay accessible for 90 days post-event. Innate Pharma focuses on oncology and uses therapeutic antibodies to enhance cancer treatment, collaborating with major biopharmaceutical companies.